One-year results from the open-label extension of the phase III MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine annual meeting, indicate that inebilizumab (Uplizna) continues to control symptoms in generalized myasthenia gravis. The analysis included patients with acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) autoantibodies, and both patient-reported MG-ADL and physician-reported QMG scores remained improved.
According to Richard Nowak of the Yale Myasthenia Gravis Clinic, patients who originally received placebo and crossed over to active drug also showed consistent clinical improvements. The data suggest that benefits may increase the longer patients are on treatment, although the study was not powered to confirm that nuance. Safety and tolerability were maintained through the additional year of follow-up.
The findings build on the randomized portion of MINT, which met its primary endpoint and supported FDA approval of inebilizumab for AChR- or MuSK-positive generalized myasthenia gravis in December 2025. Longer-term data from the extension, which can run up to three years, are expected at future meetings.